ciprofloxacin has been researched along with Infection, Mycobacterium avium-intracellulare in 32 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "During a randomized study of clarithromycin plus clofazimine with or without ethambutol in patients with AIDS and Mycobacterium avium complex (MAC) bacteremia, eight participants received additional antimycobacterial drugs following the detection of a clarithromycin-resistant isolate (MIC, > 8 micrograms/mL)." | 9.09 | Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group. ( Dubé, MP; Havlir, DV; Kemper, CA; Leedom, JM; McCutchan, JA; Sattler, FR; See, D; Tilles, JG; Torriani, FJ, 1999) |
| " avium complex bacteremia to receive either rifampin (600 mg daily), ethambutol (approximately 15 mg per kilogram of body weight daily), clofazimine (100 mg daily), and ciprofloxacin (750 mg twice daily) (the four-drug group) or rifabutin (600 mg daily), ethambutol (as above), and clarithromycin (1000 mg twice daily) (the three-drug group)." | 9.08 | A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. ( Fanning, MM; Fong, IW; Gill, MJ; Lalonde, RG; Phillips, P; Rachlis, AR; Salit, I; Shafran, SD; Singer, J; Tsoukas, CM; Walmsley, SL; Zarowny, DP, 1996) |
| "A rapid reduction in symptoms and bacteremia can be achieved as early as week 2 of therapy using an oral regimen of rifampin, ethambutol, clofazimine, and ciprofloxacin." | 9.07 | Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group. ( Bartok, AE; Chiu, J; Deresinski, SC; Feigal, DF; Kemper, CA; Leedom, JM; McCutchan, JA; Meng, TC; Nussbaum, J; Tilles, JG, 1992) |
| "A combination of clarithromycin, ciprofloxacin, and amikacin for the treatment of Mycobacterium avium-Mycobacterium intracellulare bacteremia was evaluated in 12 AIDS patients." | 7.68 | Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. ( Caccamo, F; de Lalla, F; Marone, P; Maserati, R; Nicolin, R; Rigoli, R; Scarpellini, P, 1992) |
| "We describe four additional AIDS patients with MAC disease who had a favorable clinical and microbiological response to this regimen without developing serious adverse effects after periods ranging from 4 to 12 months." | 5.28 | Successful treatment of acquired immunodeficiency syndrome-related Mycobacterium avium complex disease with a multiple drug regimen including amikacin. ( Benson, CA; Kessler, HA; Pottage, JC; Trenholme, GM, 1991) |
| "During a randomized study of clarithromycin plus clofazimine with or without ethambutol in patients with AIDS and Mycobacterium avium complex (MAC) bacteremia, eight participants received additional antimycobacterial drugs following the detection of a clarithromycin-resistant isolate (MIC, > 8 micrograms/mL)." | 5.09 | Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group. ( Dubé, MP; Havlir, DV; Kemper, CA; Leedom, JM; McCutchan, JA; Sattler, FR; See, D; Tilles, JG; Torriani, FJ, 1999) |
| " avium complex bacteremia to receive either rifampin (600 mg daily), ethambutol (approximately 15 mg per kilogram of body weight daily), clofazimine (100 mg daily), and ciprofloxacin (750 mg twice daily) (the four-drug group) or rifabutin (600 mg daily), ethambutol (as above), and clarithromycin (1000 mg twice daily) (the three-drug group)." | 5.08 | A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. ( Fanning, MM; Fong, IW; Gill, MJ; Lalonde, RG; Phillips, P; Rachlis, AR; Salit, I; Shafran, SD; Singer, J; Tsoukas, CM; Walmsley, SL; Zarowny, DP, 1996) |
| "A rapid reduction in symptoms and bacteremia can be achieved as early as week 2 of therapy using an oral regimen of rifampin, ethambutol, clofazimine, and ciprofloxacin." | 5.07 | Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group. ( Bartok, AE; Chiu, J; Deresinski, SC; Feigal, DF; Kemper, CA; Leedom, JM; McCutchan, JA; Meng, TC; Nussbaum, J; Tilles, JG, 1992) |
| "A combination of clarithromycin, ciprofloxacin, and amikacin for the treatment of Mycobacterium avium-Mycobacterium intracellulare bacteremia was evaluated in 12 AIDS patients." | 3.68 | Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. ( Caccamo, F; de Lalla, F; Marone, P; Maserati, R; Nicolin, R; Rigoli, R; Scarpellini, P, 1992) |
| "We tested the activity of the new fluoroquinolone sparfloxacin (CI-978; AT 4140) against 30 strains of Mycobacterium avium complex (MAC) isolated from patients with acquired immune deficiency syndrome." | 3.68 | In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin. ( Hadley, WK; Nassos, PS; Sanders, CA; Yajko, DM, 1990) |
| "Amikacin was well tolerated." | 2.69 | A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals. AIDS Clinical Trials Group Protocol 135 Study Team. ( Barber, TW; Currier, J; Ellner, JJ; Hafner, R; Hojczyk, P; Hooton, TM; Jacobs, MR; Limjoco, M; Parenti, DM; Powderly, WG; Simpson, G; van der Horst, C; Williams, PL, 1998) |
| " Estimates of elimination half-life (T1/2) were not affected by rifabutin (control: 0." | 1.31 | Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. ( Li, RC; Liu, XG, 2001) |
| "Ciprofloxacin was used primarily to treat Mycobacterium avium complex (MAC) infection, dosed to achieve 2-hour post-dose serum concentrations of 4-6 micrograms/ml." | 1.29 | Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. ( Berning, SE; Iseman, MD; Madsen, L; Peloquin, CA, 1995) |
| " Serial plasma samples taken under controlled conditions suggested that a decreased rate of absorption was responsible for low one-hour concentrations in one of the subjects." | 1.28 | Ciprofloxacin in patients with mycobacterial infections: experience in 15 patients. ( Kahana, LM; Spino, M, 1991) |
| "We studied patients with AIDS and DMAC and compared their survival with that of AIDS patients without DMAC but with other comparable risk factors for survival." | 1.28 | Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. ( Dubois, RE; Ellis, DA; Fann, SA; Havlik, JA; Horsburgh, CR; Kennedy, E; Thompson, SE, 1991) |
| "We describe four additional AIDS patients with MAC disease who had a favorable clinical and microbiological response to this regimen without developing serious adverse effects after periods ranging from 4 to 12 months." | 1.28 | Successful treatment of acquired immunodeficiency syndrome-related Mycobacterium avium complex disease with a multiple drug regimen including amikacin. ( Benson, CA; Kessler, HA; Pottage, JC; Trenholme, GM, 1991) |
| "Amikacin was bacteriostatic, with an MIC of 4." | 1.28 | Amikacin, ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection of beige mice. ( Inderlied, CB; Kolonoski, PT; Wu, M; Young, LS, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.25) | 18.7374 |
| 1990's | 22 (68.75) | 18.2507 |
| 2000's | 6 (18.75) | 29.6817 |
| 2010's | 1 (3.13) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, W | 1 |
| Yang, J | 1 |
| Wu, X | 1 |
| Wan, B | 1 |
| Wang, H | 1 |
| Yu, F | 1 |
| Guo, Y | 1 |
| Trone, MC | 1 |
| Manoli, P | 1 |
| Mattei, J | 1 |
| Thuret, G | 1 |
| Gain, P | 1 |
| Stephan, JL | 1 |
| Murray, MP | 1 |
| Laurenson, IF | 1 |
| Hill, AT | 1 |
| Desimone, JA | 1 |
| Babinchak, TJ | 1 |
| Kaulback, KR | 1 |
| Pomerantz, RJ | 1 |
| Pérez de Pedro, I | 1 |
| de la Quintana-Beltrán, P | 1 |
| Bermúdez-Ruiz, P | 1 |
| Valerga, M | 1 |
| Cugliari, M | 1 |
| Cefalo, E | 1 |
| Martín, M | 1 |
| Sirgel, FA | 1 |
| Venter, A | 1 |
| Heilmann, HD | 1 |
| Berning, SE | 1 |
| Madsen, L | 1 |
| Iseman, MD | 1 |
| Peloquin, CA | 2 |
| Steven, N | 1 |
| Pithie, A | 1 |
| Wood, M | 1 |
| Innes, J | 1 |
| Gordon, SM | 1 |
| Horsburgh, CR | 2 |
| Havlik, JA | 2 |
| Metchock, B | 1 |
| Heifets, L | 1 |
| McGowan, JE | 1 |
| Thompson, SE | 2 |
| Clark, JA | 1 |
| Margolis, DM | 1 |
| Jacobson, MA | 1 |
| Yajko, D | 2 |
| Northfelt, D | 1 |
| Charlebois, E | 1 |
| Gary, D | 1 |
| Brosgart, C | 1 |
| Sanders, CA | 2 |
| Hadley, WK | 3 |
| Asnis, DS | 1 |
| Bresciani, AR | 1 |
| Cohn, M | 1 |
| Shafran, SD | 2 |
| Singer, J | 2 |
| Zarowny, DP | 1 |
| Phillips, P | 1 |
| Salit, I | 2 |
| Walmsley, SL | 1 |
| Fong, IW | 1 |
| Gill, MJ | 1 |
| Rachlis, AR | 1 |
| Lalonde, RG | 1 |
| Fanning, MM | 1 |
| Tsoukas, CM | 2 |
| Fisher, M | 1 |
| Tomlinson, DR | 1 |
| Coker, RJ | 1 |
| Reisner, BS | 1 |
| Woods, GL | 1 |
| Popov, VL | 1 |
| Parenti, DM | 1 |
| Williams, PL | 1 |
| Hafner, R | 1 |
| Jacobs, MR | 1 |
| Hojczyk, P | 1 |
| Hooton, TM | 1 |
| Barber, TW | 1 |
| Simpson, G | 1 |
| van der Horst, C | 1 |
| Currier, J | 1 |
| Powderly, WG | 1 |
| Limjoco, M | 1 |
| Ellner, JJ | 1 |
| Dubé, MP | 1 |
| Torriani, FJ | 1 |
| See, D | 1 |
| Havlir, DV | 1 |
| Kemper, CA | 2 |
| Leedom, JM | 2 |
| Tilles, JG | 3 |
| McCutchan, JA | 3 |
| Sattler, FR | 1 |
| Keiser, P | 1 |
| Nassar, N | 1 |
| Skiest, D | 1 |
| Rademacher, S | 1 |
| Smith, JW | 1 |
| Thorne, A | 1 |
| Khorasheh, S | 1 |
| Raboud, JM | 1 |
| Wu, AW | 1 |
| Lemieux, C | 1 |
| Liu, XG | 1 |
| Li, RC | 1 |
| de Lalla, F | 1 |
| Maserati, R | 1 |
| Scarpellini, P | 1 |
| Marone, P | 1 |
| Nicolin, R | 1 |
| Caccamo, F | 1 |
| Rigoli, R | 1 |
| Majumdar, S | 1 |
| Flasher, D | 1 |
| Friend, DS | 1 |
| Nassos, P | 1 |
| Düzgüneş, N | 1 |
| Kahana, LM | 1 |
| Spino, M | 1 |
| Meng, TC | 1 |
| Nussbaum, J | 2 |
| Chiu, J | 2 |
| Feigal, DF | 1 |
| Bartok, AE | 1 |
| Deresinski, SC | 1 |
| Ellis, DA | 1 |
| Kennedy, E | 1 |
| Fann, SA | 1 |
| Dubois, RE | 1 |
| Benson, CA | 1 |
| Kessler, HA | 1 |
| Pottage, JC | 1 |
| Trenholme, GM | 1 |
| Yajko, DM | 1 |
| Nassos, PS | 1 |
| Bozzette, S | 1 |
| Young, LS | 2 |
| Leedom, J | 1 |
| Heseltine, PN | 1 |
| Inderlied, CB | 1 |
| Kolonoski, PT | 1 |
| Wu, M | 1 |
| Hoffner, SE | 1 |
| Kratz, M | 1 |
| Olsson-Liljequist, B | 1 |
| Svenson, SB | 1 |
| Källenius, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.[NCT00000641] | Phase 2 | 90 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ciprofloxacin and Infection, Mycobacterium avium-intracellulare
| Article | Year |
|---|---|
Rifabutin-associated uveitis in a 10-year-old child with HIV: Case report and review of the literature.
Topics: AIDS-Related Opportunistic Infections; Child; Ciprofloxacin; Drug Substitution; Female; HIV; HIV Inf | 2018 |
7 trials available for ciprofloxacin and Infection, Mycobacterium avium-intracellulare
| Article | Year |
|---|---|
Outcomes of a standardized triple-drug regimen for the treatment of nontuberculous mycobacterial pulmonary infection.
Topics: Aged; Anti-Bacterial Agents; Blood Sedimentation; Ciprofloxacin; Clarithromycin; Drug Resistance, Ba | 2008 |
Randomized, placebo-controlled trial of rifampin, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Ciprofloxacin; Double-Blind Method; Drug Synergism; Dr | 1993 |
A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antitubercular Agents; Bacterem | 1996 |
A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals. AIDS Clinical Trials Group Protocol 135 Study Team.
Topics: Adult; AIDS-Related Opportunistic Infections; Amikacin; Bacteremia; Ciprofloxacin; Clofazimine; Colo | 1998 |
Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group.
Topics: AIDS-Related Opportunistic Infections; Bacteremia; Ciprofloxacin; Clarithromycin; Clofazimine; Drug | 1999 |
Symptomatic and health status outcomes in the Canadian randomized MAC treatment trial (CTN010). Canadian HIV Trials Network Protocol 010 Study Group.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Bacteremia; Canada; | 2000 |
Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Amikacin; Anti-Infective Agents; Ba | 1992 |
24 other studies available for ciprofloxacin and Infection, Mycobacterium avium-intracellulare
| Article | Year |
|---|---|
Difference in drug susceptibility distribution and clinical characteristics between
Topics: Adult; Aged; Anti-Bacterial Agents; China; Ciprofloxacin; Clarithromycin; Cough; Doxycycline; Drug R | 2021 |
Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antiretroviral Therapy, Highly | 2003 |
[Cervical lymphadenitis due to Mycobacterium avium in an immunocompetent adult].
Topics: Accidents, Traffic; Adolescent; Ciprofloxacin; Clarithromycin; Ethambutol; Humans; Immunocompetence; | 2007 |
[Mycobacterium avium infection in a renal transplant recipient].
Topics: Adult; Anti-Bacterial Agents; Antitubercular Agents; Biopsy; Ciprofloxacin; Clarithromycin; Diagnosi | 2007 |
Comparative in-vitro activity of Bay y 3118, a new quinolone, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mycobac | 1995 |
Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections.
Topics: Antitubercular Agents; Ciprofloxacin; Drug Administration Schedule; Female; Humans; Male; Middle Age | 1995 |
Corticosteroid therapy for AIDS patients with Mycobacterium avium-intracellulare infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Azithromycin; Ciprofloxacin; Clofazimine; Drug Therapy | 1994 |
Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease.
Topics: Administration, Oral; Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agent | 1993 |
A cutaneous lesion in a patient with AIDS: an unusual presentation of infection due to Mycobacterium avium complex.
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Ciprofloxacin; Clarithromycin; D | 1993 |
Mycobacterium avium-intracellulare complex pneumonia in a non-HIV-infected individual: an increasingly recognized disease.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antitubercular Age | 1996 |
The management of mycobacterial infections in HIV seropositive individuals. Jefferiss Wing Therapeutics and Protocols Group.
Topics: Adrenal Cortex Hormones; Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitu | 1996 |
Electron microscopic analysis of Mycobacterium avium complex isolates exposed to ciprofloxacin, rifabutin, ethambutol and clarithromycin.
Topics: Antitubercular Agents; Ciprofloxacin; Clarithromycin; Dose-Response Relationship, Drug; Ethambutol; | 1997 |
A retrospective study of the addition of ciprofloxacin to clarithromycin and ethambutol in the treatment of disseminated Mycobacterium avium complex infection.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; CD4 Lymphocyte Count; Ciproflox | 1999 |
MAC management.
Topics: Acquired Immunodeficiency Syndrome; Amikacin; Antitubercular Agents; Ciprofloxacin; Clarithromycin; | 1996 |
Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice.
Topics: Absorption; Administration, Oral; Animals; Anti-Infective Agents; Antibiotics, Antitubercular; Cipro | 2001 |
Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amikacin; Bacteremia; Cause of Death; Ciprofloxacin; Clar | 1992 |
Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/macrophages.
Topics: Ciprofloxacin; Drug Carriers; Humans; Liposomes; Macrophages; Monocytes; Mycobacterium avium Complex | 1992 |
Ciprofloxacin in patients with mycobacterial infections: experience in 15 patients.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Ciprofloxacin; Drug Therapy, Combinati | 1991 |
Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy.
Topics: Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Antibiotics, Antitubercular; Ciprofloxaci | 1991 |
Successful treatment of acquired immunodeficiency syndrome-related Mycobacterium avium complex disease with a multiple drug regimen including amikacin.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amikacin; Antitubercular Agents; Ciprofloxacin; Clofazimi | 1991 |
In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin.
Topics: Acquired Immunodeficiency Syndrome; Anti-Infective Agents; Ciprofloxacin; Drug Synergism; Ethambutol | 1990 |
Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Amikacin; Chemical and Drug Induced Liver | 1990 |
Amikacin, ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection of beige mice.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ciprofloxacin; Colony Count, Microbial; Female; Imipenem; | 1989 |
In-vitro synergistic activity between ethambutol and fluorinated quinolones against Mycobacterium avium complex.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Interactions; Drug Synergism; Ethambutol; Humans; Microbi | 1989 |